NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading TPST? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it operates in a sector with favorable momentum, which could provide support.
The market appears to have priced in significant uncertainty given TPST's recent weak financial performance and high risk. Expectations may be low, reflecting the company's loss-making status and the potential for further earnings misses.
Fundamentals are likely to remain weak in the near term due to a high probability of an earnings miss. Management's mixed progress on clinical development and integration of acquired assets adds to the uncertainty.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could lift TPST, but any negative guidance from them could significantly impact TPST's prospects.
The next few months will be critical for TPST as it navigates high risks and mixed management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Many directors have left. This raises concerns about following Nasdaq rules.
Confirms:Nasdaq says compliance issues are fixed. The company stays listed.
Disproves:Nasdaq sends a delisting notice or reports more compliance problems.
Why it matters: Starting the registrational study is a key step for TPST-2003, impacting its path to market.
Confirms:The U.S. registrational study for TPST-2003 begins as scheduled in 2026-Q4.
Disproves:The study is postponed or fails to initiate by the end of 2026.
Why it matters: Updates on financial performance will show how the company handles leadership changes. This can change how investors feel.
Confirms one read:Financial performance shows key metrics improving after the CFO change.
Confirms the other:Financial performance metrics get worse or stay the same after the change.
Why it matters: Earnings results will show if the company can recover from recent misses and losses.
Confirms one read:Earnings report shows revenue growth and better financial numbers.
Confirms the other:Earnings report shows more losses or misses expectations.
Why it matters: If healthcare revenue growth speeds up, it may benefit Tempest and improve its market position.
Confirms:Healthcare revenue growth is speeding up again, nearing 10% year over year.
Disproves:Healthcare revenue growth keeps slowing down below current levels.
Why it matters: The new CFO's plan will show how Tempest will manage finances after the transition. This can impact investor confidence.
Confirms:A press release detailing the new CFO's strategic financial plan within three months.
Disproves:The new CFO has not shared any news about financial plans.
Why it matters: Dosing the first patient will show progress in Tempest's new CAR-T therapy for autoimmune diseases.
Confirms:First patient dosing in the TPST-4003 trial occurs in Q4 2026 as planned.
Disproves:Dosing is delayed beyond Q4 2026 or fails to start.
Why it matters: Fixing the Nasdaq issue is key for Tempest's listing and investor trust.
Confirms:Tempest gets proof it meets Nasdaq's equity rules.
Disproves:More Nasdaq warnings about compliance or delisting.
